Cargando…

How antimalarial drug resistance affects post-treatment prophylaxis

Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing r...

Descripción completa

Detalles Bibliográficos
Autor principal: White, Nicholas J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254426/
https://www.ncbi.nlm.nih.gov/pubmed/18186948
http://dx.doi.org/10.1186/1475-2875-7-9
_version_ 1782151186506317824
author White, Nicholas J
author_facet White, Nicholas J
author_sort White, Nicholas J
collection PubMed
description Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing recrudescence (reflecting treatment efficacy) compared with preventing reinfection (reflecting PTP) need further assessment. Antimalarial drug resistance shortens PTP. While blood concentrations are in the terminal elimination phase, the degree of shortening may be estimated from measurements of in-vitro susceptibility and the terminal elimination half-life. More information is needed on PTP following intermittent preventive treatments, and on the relationship between the duration of PTP and immunity, so that policy recommendations can have a firmer evidence base.
format Text
id pubmed-2254426
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22544262008-02-26 How antimalarial drug resistance affects post-treatment prophylaxis White, Nicholas J Malar J Review Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing recrudescence (reflecting treatment efficacy) compared with preventing reinfection (reflecting PTP) need further assessment. Antimalarial drug resistance shortens PTP. While blood concentrations are in the terminal elimination phase, the degree of shortening may be estimated from measurements of in-vitro susceptibility and the terminal elimination half-life. More information is needed on PTP following intermittent preventive treatments, and on the relationship between the duration of PTP and immunity, so that policy recommendations can have a firmer evidence base. BioMed Central 2008-01-11 /pmc/articles/PMC2254426/ /pubmed/18186948 http://dx.doi.org/10.1186/1475-2875-7-9 Text en Copyright © 2008 White; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
White, Nicholas J
How antimalarial drug resistance affects post-treatment prophylaxis
title How antimalarial drug resistance affects post-treatment prophylaxis
title_full How antimalarial drug resistance affects post-treatment prophylaxis
title_fullStr How antimalarial drug resistance affects post-treatment prophylaxis
title_full_unstemmed How antimalarial drug resistance affects post-treatment prophylaxis
title_short How antimalarial drug resistance affects post-treatment prophylaxis
title_sort how antimalarial drug resistance affects post-treatment prophylaxis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254426/
https://www.ncbi.nlm.nih.gov/pubmed/18186948
http://dx.doi.org/10.1186/1475-2875-7-9
work_keys_str_mv AT whitenicholasj howantimalarialdrugresistanceaffectsposttreatmentprophylaxis